CY1116088T1 - Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων - Google Patents

Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων

Info

Publication number
CY1116088T1
CY1116088T1 CY20151100233T CY151100233T CY1116088T1 CY 1116088 T1 CY1116088 T1 CY 1116088T1 CY 20151100233 T CY20151100233 T CY 20151100233T CY 151100233 T CY151100233 T CY 151100233T CY 1116088 T1 CY1116088 T1 CY 1116088T1
Authority
CY
Cyprus
Prior art keywords
prevention
healthcare
dangerous
therapy
heart diseases
Prior art date
Application number
CY20151100233T
Other languages
English (en)
Inventor
Frédérique Lantoine-Adam
Robert Letienne
Elisabeth Dupont-Passelaigue
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of CY1116088T1 publication Critical patent/CY1116088T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε δοκοζαεξανοϊκό πανθενυλεστέρα του παρακάτω τύπου. Επίσης, αφορά σε μία μέθοδο παρασκευής αυτού και σε φαρμακευτική σύνθεση περιλαμβάνουσα αυτόν και στην χρήση αυτού στην θεραπεία ή την πρόληψη καρδιαγγειακών ασθενειών, ιδιαιτέρως κολπικής μαρμαρυγής.
CY20151100233T 2010-08-11 2015-03-06 Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων CY1116088T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1056560A FR2963790B1 (fr) 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP11743536.2A EP2603486B1 (en) 2010-08-11 2011-08-11 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases

Publications (1)

Publication Number Publication Date
CY1116088T1 true CY1116088T1 (el) 2017-02-08

Family

ID=43754935

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100233T CY1116088T1 (el) 2010-08-11 2015-03-06 Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων

Country Status (29)

Country Link
US (2) US20130137768A1 (el)
EP (1) EP2603486B1 (el)
JP (1) JP5960695B2 (el)
KR (1) KR20140031830A (el)
CN (1) CN103025707B (el)
AR (1) AR082594A1 (el)
AU (1) AU2011288410B2 (el)
BR (1) BR112013003149A2 (el)
CA (1) CA2806154A1 (el)
CY (1) CY1116088T1 (el)
DK (1) DK2603486T3 (el)
ES (1) ES2531437T3 (el)
FR (1) FR2963790B1 (el)
HK (1) HK1180298A1 (el)
HR (1) HRP20150265T1 (el)
HU (1) HUE024560T2 (el)
IL (1) IL224632A (el)
MA (1) MA34480B1 (el)
MX (1) MX2013001506A (el)
MY (1) MY166065A (el)
NZ (1) NZ607836A (el)
PL (1) PL2603486T3 (el)
PT (1) PT2603486E (el)
RS (1) RS53896B1 (el)
RU (1) RU2593203C2 (el)
SI (1) SI2603486T1 (el)
TW (1) TWI555528B (el)
UA (1) UA109551C2 (el)
WO (1) WO2012020094A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011014386A1 (de) * 2011-03-11 2012-09-13 Hemoteq Ag Endoprothese mit einer Wirkstoffbeschichtung
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
PL3176164T3 (pl) 2014-07-30 2020-05-18 Aetas Pharma Co. Ltd. Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE496795A (el)
NL133049C (el) * 1966-02-24
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale

Also Published As

Publication number Publication date
CA2806154A1 (en) 2012-02-16
TW201208672A (en) 2012-03-01
FR2963790B1 (fr) 2012-09-28
JP2013538197A (ja) 2013-10-10
US20130137768A1 (en) 2013-05-30
SI2603486T1 (sl) 2015-04-30
RS53896B1 (en) 2015-08-31
ES2531437T3 (es) 2015-03-16
MY166065A (en) 2018-05-23
CN103025707B (zh) 2015-04-29
NZ607836A (en) 2014-12-24
HK1180298A1 (en) 2013-10-18
US20150291507A1 (en) 2015-10-15
AR082594A1 (es) 2012-12-19
RU2593203C2 (ru) 2016-08-10
KR20140031830A (ko) 2014-03-13
BR112013003149A2 (pt) 2017-03-28
IL224632A (en) 2016-12-29
HRP20150265T1 (hr) 2015-04-10
EP2603486A1 (en) 2013-06-19
EP2603486B1 (en) 2014-12-17
PT2603486E (pt) 2015-02-18
UA109551C2 (uk) 2015-09-10
AU2011288410A1 (en) 2013-03-21
FR2963790A1 (fr) 2012-02-17
AU2011288410B2 (en) 2014-05-22
JP5960695B2 (ja) 2016-08-02
TWI555528B (zh) 2016-11-01
MA34480B1 (fr) 2013-08-01
WO2012020094A1 (en) 2012-02-16
CN103025707A (zh) 2013-04-03
MX2013001506A (es) 2013-02-27
RU2013110131A (ru) 2014-09-20
HUE024560T2 (hu) 2016-02-29
PL2603486T3 (pl) 2015-05-29
DK2603486T3 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
BR112018015897A2 (pt) composições e métodos para procedimentos de cuidados com a pele invasivos e não invasivos
MX2019010601A (es) Terapia de combinacion para tratar cancer.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2013004817A (es) Enfermedad inflamatoria.
MX2012013731A (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
CY1117785T1 (el) Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
CY1117831T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
CY1116088T1 (el) Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
EA201390867A1 (ru) Композиции на основе глины и обножки, способ их получения и их применение в питании и терапевтическом лечении